Inhibition of HDAC1/2 Along with TRAP1 Causes Synthetic Lethality in Glioblastoma Model Systems
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Inhibition of HDAC1/2 Along with TRAP1 Causes Synthetic Lethality in Glioblastoma Model Systems
Authors
Keywords
-
Journal
Cells
Volume 9, Issue 7, Pages 1661
Publisher
MDPI AG
Online
2020-07-10
DOI
10.3390/cells9071661
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- H3K27me3-mediated PGC1α gene silencing promotes melanoma invasion through WNT5A and YAP
- (2020) Chi Luo et al. JOURNAL OF CLINICAL INVESTIGATION
- Efficacy of Panobinostat for the Treatment of Multiple Myeloma
- (2020) Evangelos Eleutherakis-Papaiakovou et al. Journal of Oncology
- Co-inhibition of BET proteins and PI3Kα triggers mitochondrial apoptosis in rhabdomyosarcoma cells
- (2020) Cathinka Boedicker et al. ONCOGENE
- HDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma models
- (2020) Trang Thi Thu Nguyen et al. JOURNAL OF CLINICAL INVESTIGATION
- Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas
- (2019) Jennifer K Lue et al. CLINICAL CANCER RESEARCH
- An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma
- (2019) Cyril Neftel et al. CELL
- Activation of LXR Receptors and Inhibition of TRAP1 Causes Synthetic Lethality in Solid Tumors
- (2019) Trang Thi Thu Nguyen et al. Cancers
- Activation of LXR β inhibits tumor respiration and is synthetically lethal with Bcl‐ xL inhibition
- (2019) Trang Thi Thu Nguyen et al. EMBO Molecular Medicine
- FDA-approved drug screen identifies proteasome as a synthetic lethal target in MYC-driven neuroblastoma
- (2019) Jingchao Wang et al. ONCOGENE
- Targeting pyrimidine synthesis accentuates molecular therapy response in glioblastoma stem cells
- (2019) Xiuxing Wang et al. Science Translational Medicine
- MET Inhibition Elicits PGC1α-Dependent Metabolic Reprogramming in Glioblastoma
- (2019) Yiru Zhang et al. CANCER RESEARCH
- Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies
- (2018) Varun V. Prabhu et al. CELL CYCLE
- Combined HDAC and Bromodomain Protein Inhibition Reprograms Tumor Cell Metabolism and Elicits Synthetic Lethality in Glioblastoma
- (2018) Yiru Zhang et al. CLINICAL CANCER RESEARCH
- Acetyl-CoA promotes glioblastoma cell adhesion and migration through Ca2+–NFAT signaling
- (2018) Joyce V. Lee et al. GENES & DEVELOPMENT
- An inhibitor of oxidative phosphorylation exploits cancer vulnerability
- (2018) Jennifer R. Molina et al. NATURE MEDICINE
- Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate
- (2018) Lukas Bunse et al. NATURE MEDICINE
- Actively personalized vaccination trial for newly diagnosed glioblastoma
- (2018) Norbert Hilf et al. NATURE
- Concomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells
- (2017) Tinka Haydn et al. Cell Death & Disease
- Single-Cell RNA-Seq Analysis of Infiltrating Neoplastic Cells at the Migrating Front of Human Glioblastoma
- (2017) Spyros Darmanis et al. Cell Reports
- Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors
- (2016) Gao Zhang et al. JOURNAL OF CLINICAL INVESTIGATION
- The Histone Demethylase UTX Promotes Brown Adipocyte Thermogenic Program Via Coordinated Regulation of H3K27 Demethylation and Acetylation
- (2015) Lin Zha et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Adaptive Mitochondrial Reprogramming and Resistance to PI3K Therapy
- (2015) Jagadish C. Ghosh et al. JNCI-Journal of the National Cancer Institute
- Delineation ofMGMTHypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma
- (2015) Shiv K. Gupta et al. JNCI-Journal of the National Cancer Institute
- PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway
- (2015) F. Engert et al. MOLECULAR CANCER THERAPEUTICS
- Adaptive Mitochondrial Reprogramming and Resistance to PI3K Therapy
- (2015) Jagadish C. Ghosh et al. JNCI-Journal of the National Cancer Institute
- Delineation ofMGMTHypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma
- (2015) Shiv K. Gupta et al. JNCI-Journal of the National Cancer Institute
- Acetate Is a Bioenergetic Substrate for Human Glioblastoma and Brain Metastases
- (2014) Tomoyuki Mashimo et al. CELL
- Inhibition of the mitochondrial Hsp90 chaperone network: A novel, efficient treatment strategy for cancer?
- (2013) Markus D. Siegelin CANCER LETTERS
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Landscape of the mitochondrial Hsp90 metabolome in tumours
- (2013) Young Chan Chae et al. Nature Communications
- NOXA as critical mediator for drug combinations in polychemotherapy
- (2012) H Ehrhardt et al. Cell Death & Disease
- 2-Deoxyglucose Induces Noxa-Dependent Apoptosis in Alveolar Rhabdomyosarcoma
- (2011) S. Ramirez-Peinado et al. CANCER RESEARCH
- Bortezomib Primes Glioblastoma, Including Glioblastoma Stem Cells, for TRAIL by Increasing tBid Stability and Mitochondrial Apoptosis
- (2011) T. Unterkircher et al. CLINICAL CANCER RESEARCH
- Multiple BH3 Mimetics Antagonize Antiapoptotic MCL1 Protein by Inducing the Endoplasmic Reticulum Stress Response and Up-regulating BH3-only Protein NOXA
- (2011) Tina C. Albershardt et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Exploiting the mitochondrial unfolded protein response for cancer therapy in mice and human cells
- (2011) Markus D. Siegelin et al. JOURNAL OF CLINICAL INVESTIGATION
- An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR-Dependent Pathway
- (2011) D. Guo et al. Cancer Discovery
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- Preclinical Characterization of Mitochondria-Targeted Small Molecule Hsp90 Inhibitors, Gamitrinibs, in Advanced Prostate Cancer
- (2010) B. H. Kang et al. CLINICAL CANCER RESEARCH
- Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90
- (2009) Byoung Heon Kang et al. JOURNAL OF CLINICAL INVESTIGATION
- ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells
- (2009) Q. Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
- (2009) M. G. Vander Heiden et al. SCIENCE
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
- Genomic Changes and Gene Expression Profiles Reveal That Established Glioma Cell Lines Are Poorly Representative of Primary Human Gliomas
- (2008) A. Li et al. MOLECULAR CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now